Quantcast
Last updated on April 17, 2014 at 13:30 EDT

Latest Abiraterone Stories

2013-09-20 08:25:10

WHIPPANY, N.J., Sept. 20, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo(®) (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The decision of the European Commission on the approval is expected in the second half of 2013. Xofigo...

2013-09-16 08:30:18

Nearly Half of Current Non-Prescribers Anticipate Prescribing Xofigo in the Next Four to Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one month post-launch of Algeta/Bayer HealthCare's Xofigo in the United States, approximately one quarter of surveyed U.S. medical oncologists...

2013-08-08 16:26:58

Conference call to be held on Thursday, August 8 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 8, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and apatorsen (OGX-427), and announced second quarter 2013 financial results. Custirsen Program Update -- The primary registration Phase 3 SYNERGY trial, designed to evaluate a...

2013-07-17 16:28:17

WHIPPANY, N.J., July 17, 2013 /PRNewswire/ -- Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo(®) (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM). These data supported the U.S. Food and Drug...

2013-06-17 08:28:53

Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline NEW BRUNSWICK, N.J., June 17, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation...

2013-06-05 12:30:50

Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Significant Median Overall Survival Benefit over Currently Available Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists'...

2013-05-29 08:30:11

~New indication provides physicians with option to be used earlier in treatment of the disease, with hope of delaying chemotherapy~ TORONTO, May 29, 2013 /CNW/ - Janssen Inc. announced today that Health Canada has approved the once-daily, oral medication ZYTIGA(®) (abiraterone acetate), for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen...

2013-05-23 12:27:26

Study to evaluate whether drug works better against tumors with specific genetic anomaly ANN ARBOR, Mich., May 23, 2013 /PRNewswire-USNewswire/ -- Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients - the next question is to figure out how to match the right treatments with the right patients. A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to...

2013-05-22 08:27:18

Expanding OGX-427 Clinical Development Program Demonstrates the Company's Commitment to Addressing the Challenge of Cancer Treatment Resistance BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds, custirsen and OGX-427, will be presented as...

2013-05-15 20:23:29

Note: This release corresponds to ASCO abstracts 5014, 5004, 5009, 5010, 5013, 5037, 5059, 9617, 9618, 5059, 8502, 7130, 8619, 8613, 8614, 7014, 7056, 7057, 8512 and electronic publication e17510 RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...